Update on non-executive director appointment

RNS Number : 0454O

Renalytix AI PLC

30 September 2019

 

Renalytix AI plc

("RenalytixAI" or the "Company")

Update on non-executive director appointment

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it expects to appoint an additional non-executive director and healthcare industry veteran within the coming weeks.

A qualified candidate has been identified to the Company and the process of completing regulatory due diligence is nearing completion. Further announcements will be made at the appropriate time.

For further information, please contact:

Renalytix AI plc	www.renalytixai.com
James McCullough, CEO	Via Walbrook PR
Stifel (Nominated Adviser & Joint Broker)	Tel: [phone]
Alex Price / Jonathan Senior / Ben Maddison
N+1 Singer (Joint Broker)		Tel: [phone]
Aubrey Powell / George Tzimas (Corporate Finance) Tom Salvesen / Mia Gardner (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Lianne Cawthorne	Mob: [phone]

About Kidney Disease 

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have chronic kidney disease.  It is reported that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage.  Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.

* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

For more information, visit renalytixai.com

 

END

 

 

UPDLLMRTMBJTBAL